Eli Lilly and Company initiated a recall of Trulicity (dulaglutide) on August 19, 2021. The U.S. Food and Drug Administration classified this action as a Class II recall.
The recall affected autoinjector pens labeled as 0.75 mg per 0.5 mL. According to the recall record, these devices actually contained 1.5 mg per 0.5 mL of product, a labeling error on declared strength.
The affected product was Trulicity, 0.75 mg/0.5 mL, packaged as 4 single-dose pens per box, Rx only, manufactured by Eli Lilly and Company of Indianapolis, IN 46285, under NDC 0002-1433-80.
The recall status is listed as terminated. This brief reports only the classification, reason, firm, and dates as recorded in the recall data, without implying additional safety conclusions beyond what is stated.
Readers seeking general background on this compound can consult the compound overview for additional context.